Description
Tamsulosin Retard Pharmacodynamics
Tamsulosin is a specific blocker of postsynaptic alpha1-adrenoreceptors located in the smooth muscle of the prostate, bladder neck and prostatic part of the urethra. Blockade of alpha1-adrenoreceptors by tamsulosin leads to decrease of the tone of the smooth muscles of the prostate, bladder neck and prostatic part of the urethra and improvement of the outflow of urine. Simultaneously, both symptoms of emptying and symptoms of filling caused by increased tone of smooth muscles and detrusor hyperactivity in benign prostatic hyperplasia (BPH) are reduced.
The ability of tamsulosin to influence on alpha1A subtype of adrenoreceptors is 20 times higher than its ability to interact with alpha1B subtype of adrenoreceptors, which are located in vascular smooth muscle. Due to its high selectivity, tamsulosin does not cause clinically significant reduction of systemic arterial blood pressure (BP) both in patients with arterial hypertension and in patients with normal BP values.
Indications
Treatment of dysuric disorders in benign prostatic hyperplasia.
Contraindications
Hypersensitivity to tamsulosin or any other component of the drug,
orthostatic hypotension (including in anamnesis), expressed hepatic insufficiency, children under 18 years old.
Caution
Chronic renal insufficiency (creatinine clearance (CK) less than 10 ml/min).
Arterial hypotension.
Administration during pregnancy and breast-feeding.
Tamsulosin retard is intended for use in males only.
Dosage and administration
1 film-coated, sustained-release tablet (0.4 mg) once daily should be taken orally after breakfast with water. It is not recommended to chew the tablet because this may affect the rate of drug release.
